SCHEMBL2370946

SCHEMBL2370946

COCOc1cccnc1F

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.47
CHRNA6 Q15825 1/20 0.47
CHRNA4 P43681 1/20 0.44
KCNN4 O15554 1/20 0.38
GRM5 P41594 1/20 0.36
NAPRT Q6XQN6 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
PLAU P00749 1/20 0.35
PTPN1 P18031 1/20 0.35
PDGFRB P09619 1/20 0.34
PDGFRA P16234 1/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CHRNB4 P30926 2/20 0.34
CHRNA3 P32297 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30677149 0.81 CHRNB4 (0.50) NPC1RAB9AMEN1KMT2APLAU
SCHEMBL16054964 0.81 CHRNB4 (0.50) NPC1RAB9AMEN1KMT2APLAU
SCHEMBL18833817 0.80 CHRNB2 (0.49) CHRNB2CHRNA6CHRNA4GRM5MEN1
SCHEMBL4370352 0.79
SCHEMBL29413198 0.79
SCHEMBL16237691 0.78 CHRNB2 (0.47) CHRNB2CHRNA4KCNN4NPC1RAB9A
SCHEMBL12893078 0.77 CHRNB2 (0.47) CHRNB2CHRNA6CHRNA4GRM5NPC1
SCHEMBL1445524 0.77 S1PR4 (0.47) NPC1RAB9AMEN1KMT2APLAU
SCHEMBL761705 0.77 CHRNB2 (0.44) CHRNB2CHRNA4NPC1RAB9AMEN1
SCHEMBL1848513 0.77 PLAU (0.35) KCNN4GRM5NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105209449-B Inhibitors of the kynurenine pathway 库拉德夫制药私人有限公司 2019-02-01 CN disclosed
CN-105209449-A Inhibitors of the kynurenine pathway CURADEV PHARMA PRIVATE LTD 2015-12-30 CN disclosed
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP CHRNB2 341/4885CHRNA6 51/4885CHRNA4 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.